CHEManager International

CHEManager International is the premier brand for the chemical, pharmaceutical, and biotech industries. It empowers managers and executives with a competitive edge through timely business news, expert insights, and the latest market data, enabling strategic business and investment decisions.

Current issues

2 / 2025

1 / 2025

4 / 2024

3 / 2024

2 / 2024

1 / 2024

more issues
Photo
Dossier

Circular Economy

The chemical industry is on the threshold of a new era – the age of circularity, where products are based on closed-loop value

Photo
Dossier

Flow Chemistry

The change in many chemical companies’ product portfolio away from commodities to customer-specific specialties is one of the

Photo
Dossier

Digitalization

Industry 4.0 will enable the chemical industry and related sectors to take a leap to the next level of productivity, safety, and

Photo
Dossier

CMI Innovation

(Image: ©Getty Images/Asset ID 139428 )

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

most read

Photo
06.03.2025 • News

CordenPharma Expands Peptide Manufacturing Platform in Switzerland

Contract development and manufacturing organization (CDMO) CordenPharma has finalized plans to establish a new peptide manufacturing facility in Switzerland located at Getec Park in Muttenz near Basel. This investment is part of the company’s growth initiatives with a more than €1 billion strategic investment in peptide development and manufacturing.